TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15860478

Group type: EXPERIMENTAL
Intervention: Reading aloud and arithmetic calculation training program (2-6 days a week for 6 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 12173011

Group type: EXPERIMENTAL
Intervention: Normal whole-body insulin sensitivity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low whole-body insulin sensitivity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LV extent of normoperfused segments with PET-reverse mismatch
Number of subjects: 29
Study: 10194648

Group type: EXPERIMENTAL
Intervention: 500 lux in the upper visual field
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 lux in the lower visual field
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 lux while watching television
Number of subjects: 12
Study: 7762775

Group type: COMPARATOR
Intervention: Thiopentone (4-5 mg/kg) and enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (2-2.5 mg/kg) infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (IVA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone/enflurane
Number of subjects: 40
Study: 2324538

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine (10^7.5 TCID50)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 66
Study: 6156074

Group type: EXPERIMENTAL
Intervention: Transferrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C3 proactivator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha 2-macroglobulin
Number of subjects: 0
Study: 30962095

Group type: EXPERIMENTAL
Intervention: C difficile vaccine 100 μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C difficile vaccine 200 μg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C difficile vaccine 100 μg (day regimen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C difficile vaccine 200 μg (month regimen)
Number of subjects: 100
Study: 27868385

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study: 26681191

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat®) plus treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 23385968

Group type: EXPERIMENTAL
Intervention: Having lunch
Number of subjects: 105

Group type: COMPARATOR
Intervention: Skipping lunch
Number of subjects: 105
Study: 21477658

Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine patches plus oral paracetamol (5-25 μg/h buprenorphine patches plus 1000 mg oral paracetamol q.i.d.; n=110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Co-codamol tablets (two 8/500-two 30/500 mg tablets q.i.d.; n=110)
Number of subjects: 220
Study: 18985460

Group type: EXPERIMENTAL
Intervention: Active chewing gum containing Lactobacillus reuteri (1 x 10(8) CFU/gum)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Two active chewing gums
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo chewing gums
Number of subjects: 42
Study: 17581601

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg (L)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (E)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg plus Enalapril 20 mg (L/E)
Number of subjects: 75
Study: 16281501

Group type: EXPERIMENTAL
Intervention: Telomerase reverse transcriptase (TRT) expression in PCa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Telomerase reverse transcriptase (TRT) expression in BPH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) expression in PCa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vascular endothelial growth factor (VEGF) expression in BPH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of TRT and VEGF expressions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between TRT and VEGF expressions
Number of subjects: 60
Study: 12487225

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg, twice daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, twice daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9915661

Group type: EXPERIMENTAL
Intervention: Niaspan (extended-release niacin) at a dosage of 2,000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niaspan (extended-release niacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8563995

Group type: EXPERIMENTAL
Intervention: Flexible annuloplasty ring
Number of subjects: 184

Group type: COMPARATOR
Intervention: Rigid annuloplasty ring
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of chordae tendineae
Number of subjects: 184

Group type: COMPARATOR
Intervention: Mitral valve replacement without preservation of chordae tendineae
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with chordal preservation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Mitral valve replacement without chordal preservation
Number of subjects: 184
Study: 2744295

Group type: EXPERIMENTAL
Intervention: Computerized protocol
Number of subjects: 222

Group type: COMPARATOR
Intervention: Manual records
Number of subjects: 222
Study: 941875

Group type: EXPERIMENTAL
Intervention: Supervised nonprofessional therapists
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Professional therapists
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unsupervised nonprofessional therapists
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study: 31969287

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu decoction
Number of subjects: 49
Study: 29127425

Group type: EXPERIMENTAL
Intervention: Vitamin E (804 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lipoic acid (600 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27124606

Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg/d in 2 divided doses)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 24067431

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 252

Group type: COMPARATOR
Intervention: Dapagliflozin and Placebo
Number of subjects: 252
Study: 21964738

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil (MOD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 19720213

Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate liquid for 7-15 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Historical control (not specified)
Number of subjects: 17
Study: 17241861

Group type: EXPERIMENTAL
Intervention: Tetomilast 25 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Tetomilast 50 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 16382433

Group type: EXPERIMENTAL
Intervention: SHTC (Internet-based self-help program for traumatic event-related consequences)
Number of subjects: 27

Group type: COMPARATOR
Intervention: WL (Wait-list condition)
Number of subjects: 27
Study: 12081827

Group type: EXPERIMENTAL
Intervention: Etomoxir (600 mg total over 5 doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10471167

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8687209

Group type: EXPERIMENTAL
Intervention: Rice-based ORS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sorghum-based ORS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard WHO ORS
Number of subjects: 96
Study: 2225476

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg p.o.)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus lipid-heparin plus GHRH
Number of subjects: 7

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 7
Study: 511436

Group type: EXPERIMENTAL
Intervention: UVB phototherapy (6 to 8 exposures over 2 to 5 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: UVB phototherapy (more intensive schedules)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 38
Study: 29792288

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks (n=398)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks in FENO-high participants (n=97)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks in STRATOS 2 FENO-high population (n=108)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo (n=400 in STRATOS 1, n=422 in STRATOS 2)
Number of subjects: 1207
Study: 27083315

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.3 mg administered preoperatively via lumbar puncture
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diclofenac suppository (DS) 50 mg administered at the end of surgery
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 78
Study: 24818609

Group type: EXPERIMENTAL
Intervention: Attentional retraining (AR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study: 21875244

Group type: EXPERIMENTAL
Intervention: Uncertainty forecasts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deterministic forecasts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Categorical decision advice alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of decision advice with uncertainty estimates
Number of subjects: 0
Study: 20391212

Group type: EXPERIMENTAL
Intervention: Direct measures of comparative risk perceptions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect measures of comparative risk perceptions
Number of subjects: 0
Study: 18359604

Group type: EXPERIMENTAL
Intervention: Narrative intervention (n=79): Patients wrote a story about how cancer affected their lives for at least 20 minutes once a week for three weeks.
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Questionnaire intervention (n=77): Patients filled out the McGill Pain Questionnaire.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (n=78): Patients received usual customary care during weekly medical visits.
Number of subjects: 234
Study: 16483052

Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Number of subjects: 20
Study: 12088958

Group type: EXPERIMENTAL
Intervention: Lafutidine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabeprazole
Number of subjects: 0
Study: 10585309

Group type: COMPARATOR
Intervention: Diabetic patients (n = 71)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Nondiabetic patients (n = 185)
Number of subjects: 256
Study: 9592319

Group type: EXPERIMENTAL
Intervention: Megestrol Acetate (MA) 160 mg/day orally for two weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 1910254

Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 272
Study: 6628224

Group type: EXPERIMENTAL
Intervention: Chlorophyllin 100 mg/d for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31693787

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1226
Study: 31343402

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (200 mg once or twice a day) for 1 year
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578
Study: 29520729

Group type: COMPARATOR
Intervention: Velpatasvir 100 mg single dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir ± ribavirin for 12 weeks or sofosbuvir/velpatasvir for 24 weeks
Number of subjects: 43
Study: 25687131

Group type: EXPERIMENTAL
Intervention: Mobile phone SMS for diabetes communication
Number of subjects: 515
Study: 24215017

Group type: EXPERIMENTAL
Intervention: Single time-point FGF23 measurement
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Time-averaged FGF23 measurement
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Change in FGF23
Number of subjects: 439
Study: 21292732

Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 20% silane‐coated silica
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 60% silane‐coated silica
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bis‐GMA/TEGDMA resin with 80% silane‐coated silica
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transbond XT (control group)
Number of subjects: 160
Study: 19172226

Group type: EXPERIMENTAL
Intervention: High-frequency exerciser (HFE) - continued exercise training at least 30 min at least 3 days/week
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-frequency exerciser (LFE) - exercise training at least 30 min twice per week or less
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 17301265

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (highest vs lowest quartile)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (quartiles) among men not on aspirin
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Long-chain n-6 fatty acids (highest vs lowest quartile)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Aspirin (randomized assignment)
Number of subjects: 460
Study: 15673098

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 12214460

Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin
Number of subjects: 0
Study: 9823662

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7650231

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg bid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Venlafaxine 50 mg tid
Number of subjects: 18
Study: 3353045

Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 25
Study: 30817999

Group type: EXPERIMENTAL
Intervention: HER2-peptide vaccine nelipepimut-S + GM-CSF with trastuzumab
Number of subjects: 150

Group type: COMPARATOR
Intervention: Trastuzumab + GM-CSF
Number of subjects: 150
Study: 28938963

Group type: EXPERIMENTAL
Intervention: Allogeneic human mesenchymal stem cell injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard surgical care (no injection)
Number of subjects: 20
Study: 25409551

Group type: EXPERIMENTAL
Intervention: NTG‐Valsalva maneuver
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver alone
Number of subjects: 31
Study: 24179108

Group type: EXPERIMENTAL
Intervention: Simple hand hygiene plus antiseptic hand hygiene (water and glycerin soap for 1 minute followed by 70% ethyl alcohol gel)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Antiseptic hand hygiene (70% ethyl alcohol gel until fully dry)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular hygiene group (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gel-only group (intervention)
Number of subjects: 22
Study: 16388809

Group type: EXPERIMENTAL
Intervention: Clarithromycin for 3 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 14717485

Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate) 0.05 ml injected into anterior chamber; n = 20
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (balanced salt solution) 0.05 ml injected into anterior chamber; n = 18
Number of subjects: 38
Study: 10390129

Group type: EXPERIMENTAL
Intervention: Etofibrate treatment for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standardized fatty meal
Number of subjects: 21
Study: 8888597

Group type: EXPERIMENTAL
Intervention: Thought suppression (instructions not to think about the film)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Thinking about the film (instructions to think about the film)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 2
Study: 1381626

Group type: EXPERIMENTAL
Intervention: G-CSF (230 micrograms/m2 daily subcutaneous)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (VAPEC-B chemotherapy alone)
Number of subjects: 80
Study: 6151371

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 74

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 74
Study: 31022142

Group type: EXPERIMENTAL
Intervention: Modified Z‐plasty palatoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double opposing Z‐plasty and Sommerlad palatoplasty
Number of subjects: 40
Study: 27797930

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 25755211

Group type: EXPERIMENTAL
Intervention: Nelarabine (n=47)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-nelarabine arm (n=47)
Number of subjects: 94
Study: 22554076

Group type: EXPERIMENTAL
Intervention: Stress group (political violence video clip)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No-stress group (nature video clip)
Number of subjects: 107
Study: 22254708

Group type: EXPERIMENTAL
Intervention: Real exposure to 12.5 μT magnetic fields at 60 Hz for 30 minutes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 31
Study: 19486651

Group type: EXPERIMENTAL
Intervention: Cardio group (n=66) - cardiovascular exercises for 45-60 min at 60-70% maximal oxygen uptake, 3 sessions per week
Number of subjects: 127

Group type: COMPARATOR
Intervention: Flex group (n=61) - non-cardiovascular flexibility and balance exercises, 2 sessions per week
Number of subjects: 127
Study: 17234805

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (RE)
Number of subjects: 8
Study: 15297101

Group type: EXPERIMENTAL
Intervention: Unmodified casein
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dephosphorylated casein
Number of subjects: 8
Study: 11314884

Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin plus 250 mg metronidazole every 8 hours for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo tablets every 8 hours for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Test group (antibiotics) vs. Placebo group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pg-pos subgroup (test)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pg-pos subgroup (placebo)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pg-neg subgroup (test)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pg-neg subgroup (placebo)
Number of subjects: 49
Study: 9041216

Group type: EXPERIMENTAL
Intervention: Increased serum cardiac troponin T (cTnT) concentrations greater than 0.20 micrograms/L at baseline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased serum creatine kinase MB (CK‐MB) greater than 5.0 micrograms/L at baseline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased serum cardiac troponin I (cTnI) greater than 0.8 micrograms/L at baseline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cardiac event rate over 1 year
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased ELISA cTnT levels at 1 year
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increased CK‐MB levels at 1 year
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Elevated cTnI levels at 1 year
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reanalysis of ELISA cTnT values with a newly formulated Enzymun cTnT assay
Number of subjects: 16
Study: 7946229

Group type: EXPERIMENTAL
Intervention: Behavioural training programme administered by nurses combining life skills training, active encouragement, and a token economy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no training or reinforcement)
Number of subjects: 52
Study: 2452570

Group type: COMPARATOR
Intervention: Hydrogen peroxide at 0 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 25 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 50 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 100 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 200 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 400 ppm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 800 ppm
Number of subjects: 8
Study: 29058130

Group type: EXPERIMENTAL
Intervention: Distress Thermometer (DT)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Higher DT and HADS scores
Number of subjects: 165